No, that should not be a problem. Prothena has designed their antibody immunotherapy as passive immunization against the C-terminus (CT) truncation of a-syn. CT of a-syn is believed to cause toxic fragments which causes the oligomerization, propagation and aggregation of the a-syn in the neuron. They have shown this to work in-vitro and with mouse induced PD. Now, we need to see if works in humans.

These vaccines are still years away from possible commercialized use, as they move through the clinical trial process. However, if you like the concept, and are comfortable that they are relatively safe (which the data to date has shown) you can go into the phase 2 trial. Prothena will have multiple sites throughout the US. Affiris is only conducting trials in Europe.